Taisho Pharmaceutical Co., Ltd. has filed for the global first approval of its in-house oral dual orexin 1 and 2 receptor antagonist (DORA), vornorexant (development code TS-142), for insomnia in Japan. It marks the first such filing from the Japanese OTC giant's in-house pipeline since the firm announced a business restructuring with an enhanced focus on new drug development.
The Japanese firm noted that the candidate comes with a shorter half-life compared to other DORA competitors, which can